title: Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
abstract: Identifying major antigenic and protective epitopes of the H7 hemagglutinin (HA) will be important for understanding the antibody response to vaccines developed against the novel influenza H7N9 viruses that emerged in China in 2013. To facilitate antigenic characterization of the H7N9 HA and to develop reagents for evaluation of H7N9 candidate vaccines, we generated a panel of murine monoclonal antibodies (mAbs) to the HA of A/Shanghai/2/2013 using mammalian cell-derived virus-like particles (VLP) containing the H7 HA. Neutralizing antibodies identified an HA epitope corresponding to antigenic site A on the structurally similar influenza H3 hemagglutinin. Importantly, the neutralizing antibodies protect against A/Shanghai/2/2013 challenge. This antigenic site is conserved among many H7 viruses, including strains of both Eurasian and North American lineage, and the isolated neutralizing antibodies are cross-reactive with older H7 vaccine strains. The results indicate that the identified antigenic site is a potentially important protective epitope and suggest the potential benefit of cross-reactive antibody responses to vaccination with H7 candidate vaccines.
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Falko
authors: F
authors: Schmeisser
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Anupama
authors: A
authors: Vasudevan
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Swati
authors: S
authors: Verma
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Wei
authors: W
authors: Wang
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Esmeralda
authors: E
authors: Alvarado
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Carol
authors: C
authors: Weiss
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Vajini
authors: V
authors: Atukorale
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Clement
authors: C
authors: Meseda
authors: Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America.
authors: Jerry P
authors: JP
authors: Weir
mesh_terms: D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology*; D006801:Humans; D064766:Influenza A Virus, H7N9 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000939:Epitopes; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; C109963:hemagglutinin, avian influenza A virus
references: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1356-61
references: 14745020
references: Lancet. 2004 Feb 21;363(9409):587-93
references: 14987882
references: Virol J. 2006 Aug 31;3:63
references: 16945126
references: Clin Vaccine Immunol. 2007 Nov;14(11):1425-32
references: 17913860
references: Vaccine. 2008 Mar 25;26(14):1742-50
references: 18336962
references: J Virol Methods. 2008 Nov;153(2):111-9
references: 18722473
references: Vaccine. 2009 Mar 18;27(13):1889-97
references: 19368768
references: Influenza Other Respir Viruses. 2007 Jul;1(4):157-66
references: 19432631
references: J Virol Methods. 2010 May;165(2):305-10
references: 20153374
references: Vaccine. 2012 May 14;30(23):3413-22
references: 22465746
references: Influenza Other Respir Viruses. 2013 May;7(3):480-90
references: 23122228
references: PLoS One. 2012;7(12):e49704
references: 23239968
references: J Virol. 2013 May;87(10):5746-54
references: 23487452
references: N Engl J Med. 2013 May 16;368(20):1888-97
references: 23577628
references: N Engl J Med. 2014 Feb 6;370(6):520-32
references: 23614499
references: J Virol. 2013 Jul;87(14):8235-40
references: 23698299
references: N Engl J Med. 2013 Dec 26;369(26):2564-6
references: 24224560
references: Emerg Infect Dis. 2014 Feb;20(2):192-200
references: 24447423
references: Sci Transl Med. 2014 Apr 30;6(234):234ra55
references: 24786323
references: Annu Rev Biochem. 1987;56:365-94
references: 3304138
references: Proc Soc Exp Biol Med. 1966 Jul;122(3):931-5
references: 5918973
references: Nature. 1981 Jan 29;289(5796):373-8
references: 6162101
references: Nature. 1981 Apr 23;290(5808):713-7
references: 6163993
references: Cell. 1982 Dec;31(2 Pt 1):417-27
references: 6186384